Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

Key Points

• Anti-CGRP monoclonal antibodies improve outcomes in hemiplegic migraine.
• Quantitative analysis of individual patients highlights significant benefits in migraine frequency.
• Longitudinal data indicates sustained effectiveness and safety over time.
• Findings suggest a viable treatment option for individuals suffering from hemiplegic migraine.